not sure; my gut tells me they need an investment bank to handle it for them and they would also issue shares to the investment bank and exchange get money to fund clinical trials and build the pharmaceutical side. without that deal with an investment bank i dont see the reverse split happen and that is bad news. they have 6 months or they will need to vote on whether to allow again.
Share Structure Market Value1 $27,153,770 a/o Dec 13, 2017 Authorized Shares 190,000,000 a/o Jul 10, 2017 Outstanding Shares 90,512,565 a/o Nov 07, 2017 -Restricted Not Available -Unrestricted Not Available Held at DTC Not Available Float 20,890,348 a/o Jul 10, 2017 Par Value 0.0001 Transfer Agent(s)